I think the virology division at Roche appears quite desperate. They are expecting increased sales of Pegasys next year due to "warehousing" of triple therapy patients. This was mentioned on last weeks C.C. Meanwhile scripts for Incivek are flattening.
Market Data 
Markets 
AI
